SCHEMBL21996077

SCHEMBL21996077

Cc1cccc(N2CCNC(C(F)F)C2)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 2/20 0.55
ALDH1A1 P00352 5/20 0.40
NPSR1 Q6W5P4 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
HTR1A P08908 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
HTR3A P46098 2/20 0.40
TSHR P16473 3/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 4/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
MAPT P10636 5/20 0.38
HTR7 P34969 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12164853 0.81 ADRB1 (0.63) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
SCHEMBL12164846 0.81 ADRB1 (0.63) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
SCHEMBL1907368 0.81 ADRB1 (0.63) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
SCHEMBL12164845 0.81 ADRB1 (0.63) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
SCHEMBL218837 0.72 ADRB1 (1.00) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
SCHEMBL29699369 0.72 ADRB1 (1.00) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL1894847 0.71 ADRB1 (0.96) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
Iodide SCHEMBL11457680 0.71 ADRB1 (0.96) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
Piperazine SCHEMBL27593403 0.71 ADRB1 (0.96) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL27850954 0.71 ADRB1 (0.96) ADRB1ALDH1A1NPSR1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264134-B2 Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME LLC (US) 2025-04-01 US disclosed
EP-3886845-B1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-09-04 EP disclosed
US-20230008022-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2023-01-12 US disclosed
US-20230008022-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2023-01-12 US disclosed
EP-3886845-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS Merck Sharp & Dohme Corp. (US) 2021-10-06 EP disclosed
WO-2020112581-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-06-04 WO disclosed
WO-2020112581-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008022-A1 NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU ADRB1 3264/4885ALDH1A1 328/4885NPSR1 1010/4885
US-12264134-B2 Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, AADAC ADRB1 3471/4885ALDH1A1 325/4885NPSR1 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.